Key points are not available for this paper at this time.
OBJECTIVE: Summarize the evidence on drug therapies for obstructive sleep apnea. METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. PubMed, Embase, Scopus, Web of Science, SciELO, LILACS, Scopus, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched on February 17th, 2023. A search strategy retrieved randomized clinical trials comparing the Apnea-Hypopnea Index (AHI) in pharmacotherapies. Studies were selected and data was extracted by two authors independently. The risk of bias was assessed using the Cochrane Risk of Bias tool. RevMan 5.4. was used for data synthesis. RESULTS: 4930 articles were obtained, 68 met inclusion criteria, and 29 studies (involving 11 drugs) were combined in a meta-analysis. Atomoxetine plus oxybutynin vs placebo in AHI mean difference of -7.71 (-10.59, -4.83) Fixed, 95 % CI, I2 = 50 %, overall effect: Z = 5.25, p < 0.001. Donepezil vs placebo in AHI mean difference of -8.56 (-15.78, -1.33) Fixed, 95 % CI, I2 = 21 %, overall effect: Z = 2.32, p = 0.02. Sodium oxybate vs placebo in AHI mean difference of -5.50 (-9.28, -1.73) Fixed, 95 % CI, I2 = 32 %, overall effect: Z = 2.86, p = 0.004. Trazodone vs placebo in AHI mean difference of -12.75 (-21.30, -4.19) Fixed, 95 % CI, I2 = 0 %, overall effect: Z = 2.92, p = 0.003. CONCLUSION: The combination of noradrenergic and antimuscarinic drugs shows promising results. Identifying endotypes may be the key to future drug therapies for obstructive sleep apnea. Moreover, studies with longer follow-up assessing the safety and sustained effects of these treatments are needed. PROSPERO REGISTRATION NUMBER: CRD42022362639.
Nobre et al. (Mon,) studied this question.